SpaceX Stock Is Down 23% From Its Post-IPO High. History Says This Will Happen Next. (Hint: It's a Big Move.)

SpaceX is down 23% from its post-IPO peak of $202 to $156, and the article argues the stock could fall much further based on historical large-IPO patterns. The company trades at 104x sales on $19.3 billion of trailing revenue, nearly 2x Palantir’s 55x sales valuation, while analysts still see $238.50 per share, implying 53% upside. The piece is primarily a valuation cautionary note rather than new company-specific fundamentals.

Analysis

The key market implication is not just that the new issue is expensive, but that it can act as a de facto sentiment tax on the entire private-growth complex. When a marquee asset reprices lower after an initial euphoria phase, it tends to compress the multiple band for adjacent names with similar narrative characteristics, especially late-stage venture and recent de-SPACs that were already trading on scarcity value rather than fundamentals. That creates relative pressure on the weakest balance-sheet names first, while profitable, cash-generative platforms with durable reinvestment runway should be comparatively insulated.

The more important second-order effect is flow-related: a fast drawdown in a headline listing often forces a reset in anchor/VC mark assumptions, which can tighten secondary-market liquidity and slow new issuance across the ecosystem for one to two quarters. That matters for names like COIN, HOOD, SNOW, PATH, and RIVN, where public comps are still used in private valuation stacks; a lower comp set can delay financing rounds, increase dilution risk, or push companies to prioritize cash preservation over growth, all of which are negative for near-term multiple support.

The contrarian point is that extreme valuation does not automatically imply immediate downside if supply is constrained. In the next few weeks, the stock can remain technically supported by post-IPO scarcity, retail enthusiasm, and analyst targets anchored to long-duration optionality. But over a 3-9 month horizon, the asymmetry still looks poor: any disappointment in launch cadence, margin structure, or capital intensity will likely matter more than topline growth, and the market is unlikely to tolerate a 100x sales multiple without visible path to operating leverage.

Key Decisions for Investors

• Short the weakest long-duration comp basket (RIVN, PATH, HOOD) vs long NFLX or V as a quality-growth hedge for the next 1-3 months; target 10-15% relative downside if post-IPO multiple compression spreads.
• Reduce exposure to secondary beneficiaries of venture liquidity such as SNOW and COIN on rallies; use 4-8 week trailing stops because these names typically de-rate first when private-market marks come under pressure.
• Pair long PLTR vs short a basket of unprofitable high-multiple growth names (RIVN/HOOD/PATH) over 1-2 quarters; PLTR should hold up better if the market rotates from narrative to cash flow durability.
• Avoid initiating new longs in recent IPO / de-SPAC exposures until the first 20-30% post-listing retracement is complete; history suggests better entry points emerge after the initial supply overhang clears.
• If listed options are available, buy medium-dated puts or put spreads on the most crowded high-beta comp names rather than on the headline issue itself; implied vol is likely more favorable where investor positioning is already extended.